Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inhibitor TherapeuticsINTI Buyback Yield % is 0.00 as of Aug. 01, 2026. The stock has 1 warning sign investors should review. Among 735 Biotechnology companies, Inhibitor Therapeutics ranks worse than 136054.29% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
Inhibitor Therapeutics Buyback Yield % Related Terms
Inhibitor Therapeutics Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Inhibitor Therapeutics's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INTI vs TPST, AKTX, ICU: Buyback Yield % Comparison
For the Biotechnology subindustry, Inhibitor Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inhibitor Therapeutics Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inhibitor Therapeutics's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Inhibitor Therapeutics's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhibitor Therapeutics (INTI) has a Buyback Yield % of 0.00 as of Aug. 01, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Inhibitor Therapeutics and its competitors. According to the industry distribution chart, Inhibitor Therapeutics ranks #999999 out of 735 companies in the Biotechnology industry.
Is Inhibitor Therapeutics' Buyback Yield % too high?
Inhibitor Therapeutics' current Buyback Yield % is 0.00. Based on the distribution chart, Inhibitor Therapeutics ranks #999999 out of 735 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Inhibitor Therapeutics' Buyback Yield % compare to TPST and AKTX?
According to the Biotechnology industry distribution chart, Inhibitor Therapeutics ranks #999999 out of 735 companies for Buyback Yield %. This places Inhibitor Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Inhibitor Therapeutics and its competitors. Inhibitor Therapeutics's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhibitor Therapeutics stock overvalued right now?
Inhibitor Therapeutics (INTI) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Inhibitor Therapeutics (INTI), the current Buyback Yield % is 0.00 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Inhibitor Therapeutics Inc is a pharmaceutical development company focused on developing and potentially commercializing therapeutics based on already approved active pharmaceutical ingredients, with a primary focus on basal cell carcinoma nevus syndrome (BCCNS), also known as Gorlin Syndrome. The Company develops therapeutics with patent-protected methods of use or delivery for certain cancers and non-cancerous proliferation disorders, and focuses on therapies for basal cell carcinoma (BCC) in the United States, utilizing itraconazole, an FDA-approved drug for fungal infections, with developed intellectual property and know-how related to the treatment of cancer patients using itraconazole.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INTI has been successfully added to your 
